Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) Closed Down 2.15% at 13.650 HKD
Newtimespace News, as of the close on May 18, Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) closed at 13.650 HKD, down 2.15%. The ETF opened at 13.830 HKD, with a session high of 13.930 HKD and a low of 13.510 HKD. The latest trading volume was 5.2676 million units, with a latest turnover of 71.7821 million HKD. The asset size is approximately 2.172 billion HKD.
Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) tracks the Hang Seng Biotechnology Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to reflect the overall performance of biotechnology companies listed in Hong Kong, covering companies in fields such as pharmaceuticals, biotechnology, and healthcare. It is one of the important market benchmarks reflecting the trend of the biotechnology sector in Hong Kong.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
- CHINAHONGQIAO (01378.HK): Revises Annual Caps under Industrial Products Purchase Agreement, 2027 Cap Raised to RMB 26.24 Million